OraSure Technologies (NASDAQ:OSUR) Chief Financial Officer Kenneth J. McGrath purchased 32,300 shares of the companys common stock on March 20, 2026, in a transaction that totaled $94,600. The purchase was executed through a pre-arranged Rule 10b5-1 trading plan that the company says was adopted on November 28, 2025.
The shares were acquired at a weighted average price of $2.9288 per share, with individual executions ranging from $2.86 to $2.98. After the transaction settled, McGrath directly owned 589,562 shares of OraSure Technologies.
The purchase takes place against a mixed performance backdrop for the stock. OraSures shares have climbed 27% year-to-date, while remaining roughly 10% lower than they were a year ago. Analysis from InvestingPro cited in company materials indicates the stock is trading below its Fair Value, and notes that OSUR is among more than 1,400 U.S. equities covered in a Pro Research Report offering.
Recent company results and investor activity provide additional context for the insider purchase. OraSure reported Q4 2025 revenue of $26.8 million, a figure that missed consensus expectations of $28.08 million by approximately 4.6%. The company disclosed improvements in gross margins but continues to confront funding constraints and operational losses.
Shareholder dynamics at OraSure have shifted as well. Altai Capital Management, which holds a 5% stake in the company, has sought board changes and nominated Rishi Bajaj and John Bertrand for election at OraSures 2026 annual shareholder meeting. Management has also outlined plans for product launches during 2026, a point referenced as a potential growth vector amid current headwinds.
McGraths purchase under the 10b5-1 arrangement is a formalized approach that allows scheduled trading even when insiders might otherwise be restricted from transacting. The filing indicates the direct purchase was part of that pre-established plan rather than an ad hoc buy.
Investors and market watchers will likely balance the insider purchase against the companies recent revenue shortfall, ongoing funding and operational loss issues, and the influence of activist shareholders as OraSure progresses through planned product introductions later in 2026.